Digilab, Inc. today
announced it has reached an important milestone in its Peptidomics
collaboration with Abbott Molecular. In the first phase of the project,
Digilab has identified candidate biomarkers for lung cancer using its
proprietary Peptidomics(R) Differential Peptide Display (DPD) technology
platform. Abbott has exercised its right to evaluate option candidate
markers for further use. Abbott has the option to acquire an exclusive
royalty-bearing license from Digilab to such candidate markers.
David Giddings, President and CEO of Digilab, Inc. and Dr. Wolfram
Rodatz, Managing Director Digilab BioVisioN GmbH, commented on the success:
"The project with Abbott now enters a promising new phase for Digilab. Our
Hannover Germany based Peptidomics-approach to biomarker discovery has once
again shown that it is able to provide molecular identification of peptide
candidate markers very efficiently and reliably."
About Digilab
As a global leader in molecular spectroscopy systems for almost 40
years, Digilab develops innovative and differentiated products and services
for the life sciences research and in-vitro diagnostics markets. The
company's pioneering work for the U.S. Government in 1969 led to the
development, manufacture, sales and service of the first commercial
Fourier-Transform InfraRed (FTIR) spectrometer. In the fall of 2004,
Digilab sold its FTIR molecular spectroscopy assets to Varian Inc. Since
then, the company has remained focused on novel and proprietary sample
prep, bioinformatics, and spectroscopy detection/analysis devices which can
be integrated into solutions for research and diagnostics applications.
In February 2006 Digilab acquired BioVisioN, AG in Hannover, Germany.
Digilab is globally commercializing Digilab BioVisioN GmbH's patented
Peptidomics(R) products and services and generating IP in this space.
Digilab works with companies from the pharmaceutical and diagnostics
sectors; analytical instrumentation hardware, software, and consumables
suppliers; and academic institutions and government agencies. Digilab has
had engagements to discover new biomarkers or drug targets with such
companies as Astra Zeneca, Boehringer Ingelheim, Merck & Co, Novartis, Novo
Nordisk, Roche Diagnostics, Abbott, Johnson and Johnson, and Solvay
Pharmaceuticals.
Digilab, Inc.
digilabglobal